Gain Therapeutics (NASDAQ:GANX) Shares Up 10.4% – Should You Buy?

Gain Therapeutics, Inc. (NASDAQ:GANX) was up 10.4% on Wednesday . The company traded as high as $2.45 and last traded at $2.44. Approximately 255,189 shares changed hands during mid-day trading, an increase of 23% from the average daily volume of 207,210 shares. The stock had previously closed at $2.21.

Analyst Ratings Changes

A number of research analysts have weighed in on GANX shares. Roth Capital upgraded Gain Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Roth Mkm reiterated a “buy” rating and issued a $7.00 target price on shares of Gain Therapeutics in a research report on Tuesday, December 24th. Finally, HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Gain Therapeutics in a report on Monday, November 25th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $7.25.

Gain Therapeutics Trading Down 1.1 %

The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $69.22 million, a PE ratio of -2.37 and a beta of 0.14. The business’s fifty day moving average price is $2.03 and its 200 day moving average price is $1.80.

Institutional Trading of Gain Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of GANX. Geode Capital Management LLC increased its stake in shares of Gain Therapeutics by 48.0% during the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after acquiring an additional 88,236 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Gain Therapeutics by 154.2% during the second quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock worth $152,000 after purchasing an additional 72,000 shares during the period. Jones Financial Companies Lllp boosted its stake in shares of Gain Therapeutics by 83.6% during the 4th quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company’s stock valued at $212,000 after buying an additional 44,750 shares during the period. Benedict Financial Advisors Inc. purchased a new stake in shares of Gain Therapeutics during the 4th quarter worth about $35,000. Finally, Sprott Inc. acquired a new stake in shares of Gain Therapeutics in the 4th quarter valued at $30,000. 11.97% of the stock is owned by hedge funds and other institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.